Companies in #Cardiovascular

Abbott Laboratories is a global healthcare company that researches, develops, manufactures, and distributes a diverse portfolio of health solutions across medical devices, diagnostics, nutritional products, and established pharmaceuticals. Key products include FreeStyle Libre (CGM), Ensure/Similac (nutrition), Alinity (diagnostics), and MitraClip (structural heart).

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. With Phase 3 data showing a 'potentially best-in-class profile,' Arrowhead plans to submit plozasiran for FDA approval by year-end to rival Ionis's Tryngolza in severe hypertriglyceridemia.

Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company with a strong oncology franchise (Opdivo, Yervoy, Reblozyl, Pomalyst, Empliciti), hematology, cardiovascular (Eliquis), and immunology (Sotyktu, Zeposia, deucravacitinib). BMS is investing in cell therapy, radiopharmaceuticals, and next-generation immuno-oncology platforms.

Global biopharmaceutical company (NYSE: BMY) focused on oncology, hematology, immunology, cardiovascular, neuroscience and fibrotic disease; marketed assets include Opdivo (nivolumab), Yervoy, Revlimid, Eliquis (apixaban with Pfizer), Pomalyst, Sprycel, Reblozyl, Sotyktu, deucravacitinib and the cardio-failure drug Camzyos; major acquisitions: Celgene ($74B, 2019), MyoKardia ($13B, 2020), Turning Point Therapeutics ($4.1B, 2022), Karuna Therapeutics ($14B, 2024), RayzeBio ($4.1B, 2024).

Clinical-stage biotechnology company developing pre-hospital therapies for heart attacks, led by zalunfiban (RUC-4), an investigational subcutaneous GPIIb/IIIa platelet inhibitor designed for first-medical-contact treatment of STEMI.

Early-stage medical device company advancing next-generation intravascular lithotripsy (IVL) technology for peripheral artery disease. Received FDA IDE approval for pivotal trial of Artero system.

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of generic, branded, and injectable pharmaceutical products. It is a leading supplier of sterile injectable medicines in the U.S. and operates one of the largest generics businesses in the MENA region.

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation operating through two business segments: Innovative Medicine and MedTech. It is one of the world's largest and most diversified healthcare companies, with products spanning oncology, immunology, neuroscience, cardiovascular, and surgical technologies.

Clinical-stage cell therapy company developing laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy, for hypoplastic left heart syndrome, Alzheimer's disease and aging frailty.

Clinical-stage cardioendocrine company developing MAR001, an antibody targeting remnant cholesterol, and MAR002 for acromegaly.

Italian pharmaceutical company specializing in biologics, CDMO services, and specialty pharmaceuticals. Active in European and global markets with recent expansion into obesity therapeutics via GLP-1 licensing deals.

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world, developing innovative medicines in therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology.

Medical device company developing pulmonary artery denervation technology for the treatment of pulmonary hypertension and related cardiovascular conditions.

Clinical-stage biopharmaceutical company developing tissue-targeted PDE5 inhibitor RTN-001 for uncontrolled and resistant hypertension and other serious cardiovascular conditions.

Hong Kong-listed (HKEX: 1177) pharmaceutical conglomerate specializing in biopharmaceuticals, modern Chinese medicine, and chemical medicines. Therapeutic focus on hepatobiliary, oncology, cardiovascular, and respiratory diseases.

Sunshine Biopharma is a pharmaceutical company that develops and commercializes generic and specialty prescription drugs in Canada and the United States, alongside an early-stage research pipeline in antivirals and oncology. Its research programs include SBFM-PL4, a protease inhibitor being developed for SARS coronavirus infections, and K1.1 mRNA, a lipid nanoparticle candidate for liver cancer. The commercial side of the business markets a portfolio of generic prescription medications spanning osteoporosis, cardiovascular, hypertension, anti-inflammatory, diabetes, oncology, gastroenterology, dermatology, women's health and central nervous system indications, and the company also sells consumer health products including the Essential 9 amino-acid capsules and Calcium-Vitamin D supplements. The company is headquartered in Fort Lauderdale, Florida and trades on the Nasdaq Capital Market, where it has undertaken two reverse stock splits within a year — a 1-for-10 split effective June 1, 2026, and a written-consent authorization on September 15, 2026 for a further split of up to 1-for-20 — in both cases to maintain compliance with the exchange's minimum bid price requirement.

Enterprise-ready clinical AI company pioneering autonomous clinical AI for continuous patient care between scheduled visits. Selected by ARPA-H to lead the ADVOCATE program for AI-driven cardiovascular care management.

French health technology company that designs and manufactures connected health devices including smart scales, blood pressure monitors, thermometers, and the new StethO Sense for heart and lung sound analysis.